Argent Advisors Inc. Invests $31,000 in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Argent Advisors Inc. acquired a new position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 20,000 shares of the biotechnology company’s stock, valued at approximately $31,000.

Other institutional investors also recently modified their holdings of the company. Anfield Capital Management LLC lifted its stake in Heron Therapeutics by 5.6% in the 4th quarter. Anfield Capital Management LLC now owns 118,976 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 6,264 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Heron Therapeutics by 0.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,105,803 shares of the biotechnology company’s stock valued at $1,692,000 after acquiring an additional 9,418 shares during the period. Glenmede Trust Co. NA increased its position in shares of Heron Therapeutics by 49.6% during the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock worth $63,000 after buying an additional 10,578 shares during the period. Principal Financial Group Inc. increased its position in shares of Heron Therapeutics by 10.6% during the fourth quarter. Principal Financial Group Inc. now owns 113,560 shares of the biotechnology company’s stock worth $174,000 after buying an additional 10,909 shares during the period. Finally, Zacks Investment Management increased its position in shares of Heron Therapeutics by 2.4% during the third quarter. Zacks Investment Management now owns 475,575 shares of the biotechnology company’s stock worth $946,000 after buying an additional 11,320 shares during the period. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Stock Performance

Shares of HRTX opened at $2.39 on Tuesday. The firm has a market cap of $364.07 million, a price-to-earnings ratio of -13.28 and a beta of 1.55. Heron Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $3.93. The firm has a 50 day moving average price of $1.86 and a 200-day moving average price of $1.74.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The firm had revenue of $40.78 million for the quarter, compared to the consensus estimate of $37.37 million. As a group, equities research analysts predict that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on HRTX. StockNews.com cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 8th. Needham & Company LLC reissued a “buy” rating and set a $4.00 price target on shares of Heron Therapeutics in a research report on Friday, February 28th.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.